JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

20.59 -0.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.49

Max

21.05

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

60.328

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.6% upside

Dividenden

By Dow Jones

Volgende Winsten

28 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

95M

1.1B

Vorige openingsprijs

20.93

Vorige sluitingsprijs

20.59

Nieuwssentiment

By Acuity

29%

71%

114 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 apr 2026, 23:33 UTC

Winsten

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 apr 2026, 22:40 UTC

Winsten

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 apr 2026, 22:10 UTC

Acquisities, Fusies, Overnames

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:11 UTC

Winsten

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 apr 2026, 21:01 UTC

Winsten

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 apr 2026, 23:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 apr 2026, 23:46 UTC

Marktinformatie

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 apr 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 apr 2026, 23:16 UTC

Winsten

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 apr 2026, 23:15 UTC

Winsten

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 apr 2026, 22:54 UTC

Winsten

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 apr 2026, 22:54 UTC

Winsten

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 apr 2026, 22:52 UTC

Winsten

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 apr 2026, 22:51 UTC

Winsten

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 apr 2026, 22:31 UTC

Winsten

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 apr 2026, 22:31 UTC

Winsten

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 apr 2026, 22:30 UTC

Winsten

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 apr 2026, 22:30 UTC

Winsten

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 apr 2026, 22:29 UTC

Winsten

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 apr 2026, 22:28 UTC

Winsten

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 apr 2026, 22:28 UTC

Winsten

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 apr 2026, 22:27 UTC

Winsten

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 apr 2026, 22:06 UTC

Marktinformatie
Winsten

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:47 UTC

Winsten

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:37 UTC

Winsten

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 apr 2026, 21:34 UTC

Winsten

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 apr 2026, 21:29 UTC

Winsten

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:20 UTC

Marktinformatie
Winsten

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

20.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  20.6%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

114 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat